<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613484/" ref="ordinalpos=2513&amp;ncbi_uid=1656627&amp;link_uid=PMC2613484" image-link="/pmc/articles/PMC2613484/figure/F3/" class="imagepopup">Fig. 3. TNFR and LTβR <span class="highlight" style="background-color:">signaling</span> pathways.  From: Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. </a></div><br /><div class="p4l_captionBody">Components in the TNFR1 and LTβR pathways for NF-κB activation. TNFR1 can access TRAF2 to activate the canonical NF-κB pathway RelA(p50/p65) via IκB degradation. This pathway controls many inflammatory genes and p100 synthesis. The LTβR induces both the canonical and the RelB NF-κB pathway via the NIK-IKKα-mediated processing of p100 and activation of p52/ RelB target genes.</div></div>